Years before Novo Nordisk's obesity drug Wegovy became a U.S. blockbuster, then-CEO Lars Rebien Sorensen told a press ...

Whichever way the tariff winds blow (and I've no special knowledge of that), Novo Nordisk stock remains arguably the cheapest ...

Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Novo Nordisk manufactures much of its GLP-1 drugs in Denmark. The president delayed implementation of the tariff over the weekend. Over the weekend, President Trump offered to delay implementation ...

Denmark’s exports will grow clearly less than expected earlier, partly due to the setbacks Novo Nordisk A/S is facing in the ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk A/S Bagsværd, Denmark, 16 May 2025 – Novo Nordisk today announced changes to its executive leadership and Board of Directors. As per mutual agreement with the Novo Nordisk Board ...

Novo Nordisk, maker of weight loss drug Wegovy, says CEO Lars Fruergaard Jorgensen is leaving the company by "mutual agreement." ...

Russian drugmaker Geropharm has received a compulsory license from the Russian state to produce a generic of Ozempic ...

In a letter to the Department of Commerce, Novo Nordisk argued that unsanctioned compounded semaglutide, mostly from China, ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in developing anti-obesity medicines, with Novo Nordisk (NYSE: NVO) ...

The US drugmaker has stolen a march on Novo Nordisk by bringing a viable oral weight-loss medicine, orforglipron, into successful phase 3 clinical trials. An oral version is the holy grail for drugs ...